Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Shares Outstanding (Weighted Average) (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Shares Outstanding (Weighted Average) data on record, last reported at $41.9 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 1058.24% year-over-year to $41.9 million; the TTM value through Sep 2025 reached $41.9 million, up 1058.24%, while the annual FY2024 figure was $13.2 million, 762.01% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $41.9 million in Q3 2025 per ZBIO's latest filing, roughly flat from $41.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $41.9 million in Q3 2025 and bottomed at $1.5 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $18.4 million, with a median of $8.4 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 762.01% in 2024, then skyrocketed 2589.73% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $1.5 million in 2023, then surged by 762.01% to $13.2 million in 2024, then soared by 217.78% to $41.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $41.9 million in Q3 2025, $41.8 million in Q2 2025, and $41.8 million in Q1 2025.